## axinn

# Axinn Wins Summary Judgment on Behalf of Mutual Pharmaceutical Company

NEWS | 1 MIN READ

March 4, 2010

On May 4th, 2010, the U.S. District Court for New Jersey granted Mutual Pharmaceutical's motion for summary judgment in a patent dispute with Tyco Healthcare Group over the sleepaid drug Temazepam, according to Axinn, lead counsel for Mutual.

Tyco's patent claimed low dose temazepam capsules for the treatment of insomnia. Mutual demonstrated that the use of low dose temazepam capsules were a well-known and recognized treatment for insomnia. Based on evidence presented by Mutual, the Court found that "the problem of finding a treatment of insomnia with minimal adverse effects was a known problem at the time of the invention. The solution – use of 7.5mg dose of temazepam – was not merely an obvious solution at the time of invention; as the [prior art] shows, it was a known solution."

Mutual obtained FDA approval for its generic version of Tyco's 7.5 mg temazepam capsule in September 2009. With the court's refusal to enjoin Mutual's launch in August 2009 and the invalidation of Tyco's patent, Mutual's way has been cleared to continue production of its generic drug without having to pay Tyco any damages for patent infringement.

A copy of the court's opinion can be found here:

## **Related People**



Jason Murata



Thomas K. Hedemann

#### **Related Services**

Intellectual Property

To subscribe to our publications, click here.

# **Attachments**

±153\_5-4-2010 OBVIOUSNESS ORDER

# **Featured Insights**

- ACI Forum on Pharma & Biotech Patent Litigation USA 2025
  SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- CCWC 21st Annual Career Strategies Conference SPEAKING ENGAGEMENT
- Fordham 52nd Annual Conference on International Antitrust Law and Policy SPEAKING ENGAGEMENT ANTITRUST

- Kisaco Research Trade Secret Legal Protection Conference 2025
  SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- SCCE 23rd Annual Compliance & Ethics Institute
  SPEAKING ENGAGEMENT ANTITRUST
- 29th Annual IBA Competition Conference sponsorship Antitrust
- Key Appellate Decisions Shaping Antitrust Strategy
  WEBINAR ANTITRUST
- New Frontiers of Antitrust 16th Annual International Conference of Concurrences Review SPEAKING ENGAGEMENT ANTITRUST
- MCCA Pathways Conference sponsorship Antitrust
- HNBA/VIA Annual Convention 2025
  SPONSORSHIP ANTITRUST

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved